RUA Bioscience Limited Ordinary Shares
RUA.NZXHealth Care
Rua is a New Zealand pharmaceutical company that is aiming to be a leading producer of cannabinoid derived medicines. The Company was established in 2017 in part to support local economic development in the Tairāwhiti (East Coast) region, and is a pioneer in the New Zealand medicinal cannabis sector. It was the first company in New Zealand to obtain a licence to cultivate cannabis for research purposes and the Company’s co-founder was actively involved in both the establishment of the key industry association and the development of the regulatory framework that is now in place to govern the sector. Rua will operate in the research, cultivation, extraction and manufacturing parts of the medicinal cannabis supply chain.
Market Data
$0.036
+0.1%$12.2M
-2.5x
$-0.015
0.00%
-0.1%
Latest Earnings
Half-Year Financial Results: Significant sales growth
27 February 2026
Rua Bioscience reported HY FY26 revenue of NZD $1.33M, a 92% increase over the prior corresponding period, driven by expansion across five markets including Germany, Australia, New Zealand, Czech Republic, and the UK. Despite the strong top-line growth, the net loss before tax improved only marginally to $1.79M from $1.80M, as higher financing costs, non-cash share allocation costs, and stock adjustments offset the revenue gains. The company raised $2.02M (net) via a rights offer and placement, and operating cash outflows improved 22% to $1.52M, though going concern remains a key consideration. Key points: Revenue from customers grew 92% to NZD $1.33M (HY FY26 vs HY FY25), demonstrating strong commercial momentum.; Successfully operating in five international markets: Germany, Australia, New Zealand, Czech Republic, and the UK.; Operating cash outflows improved 22% to $1.52M, reflecting the benefits of the capital-light outsourced manufacturing model.
Recent Announcements
RUA - Trading to resume at market open
NZX announced that trading in Rua Bioscience Limited (RUA) ordinary shares will resume at market open following the company's announcement on Monday, 13 July 2026. Trading had been suspended and is now being lifted by the exchange.
Significant UK market expansion through major agreement
Rua Bioscience Limited (NZX: RUA) announced a major sales and distribution agreement with a leading UK medicinal cannabis clinic and distributor, expected to generate over NZ$10 million in revenue over two years, marking the company's significant expansion into the rapidly growing UK medical cannabis market.
Significant UK market expansion through major agreement
Rua Bioscience Limited (NZX: RUA) has signed a major sales and distribution agreement with a leading UK medicinal cannabis clinic and distributor, expected to generate over NZ$10 million in revenue over two years through supplying New Zealand-grown medical cannabis flower to the United Kingdom market.
Rua Bioscience Limited (“RUA”) – Trading Halt of Securities
Rua Bioscience Limited (NZX: RUA) requested a trading halt on its ordinary shares effective immediately until market open Monday, 13 July 2026, citing a signed agreement with an international UK-listed counterparty that cannot be disclosed until a joint announcement is made to avoid uninformed trading.
Rua Bioscience Limited (“RUA”) – Trading Halt of Securities
Rua Bioscience Limited (RUA) has been placed on trading halt for its ordinary shares effective before market open on July 8, 2026, following an application approved by NZ RegCo at the issuer's request. The company's trading halt application details will be released shortly.
Ongoing Disclosure Notice - Paul Naske
Paul Naske, CEO of Rua Bioscience Limited, acquired 1,400,000 ordinary shares on 21-May-26 as part of a long-term incentive plan at $0.028 per share ($39,200 total consideration), increasing his shareholding from 1,562,372 to 2,962,372 shares.
Capital Change Notice
Rua Bioscience Limited issued 1,400,000 ordinary shares at zero cash consideration to its CEO as part of a long-term incentive plan, representing 0.41% of total shares and warrants on issue, bringing total ordinary shares to 339,441,705.
Rua Bioscience Market Update
Rua Bioscience issued a market update highlighting expansion across five international medicinal cannabis markets, including the establishment of RUA Genetics in Canada and new product launches planned in Czechia and New Zealand, while noting market challenges in Australia due to TGA regulatory review and competitive pressures in Germany following delayed regulation reform.
Expansion into Canada with New Zealand genetics export
Rua Bioscience has expanded into the Canadian market by exporting four cannabis varieties to Canadian nursery Apollo Green in March 2026, marking the first known legal export of live cannabis genetics from New Zealand and first import into Canada. The partnership enables Rua to enter Canada's regulated adult-use cannabis market, valued at approximately CAD$4-5 billion annually.
Half-Year Financial Results: Significant sales growth
Rua Bioscience reported HY FY26 revenue of NZD $1.33M, a 92% increase over the prior corresponding period, driven by expansion across five markets including Germany, Australia, New Zealand, Czech Republic, and the UK. Despite the strong top-line growth, the net loss before tax improved only marginally to $1.79M from $1.80M, as higher financing costs, non-cash share allocation costs, and stock adjustments offset the revenue gains. The company raised $2.02M (net) via a rights offer and placement, and operating cash outflows improved 22% to $1.52M, though going concern remains a key consideration. Key points: Revenue from customers grew 92% to NZD $1.33M (HY FY26 vs HY FY25), demonstrating strong commercial momentum.; Successfully operating in five international markets: Germany, Australia, New Zealand, Czech Republic, and the UK.; Operating cash outflows improved 22% to $1.52M, reflecting the benefits of the capital-light outsourced manufacturing model.
Get real-time alerts for RUA
Receive AI-powered earnings summaries and instant notifications when RUA Bioscience Limited Ordinary Shares releases results.
Register Free